Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings
Source: Streetwise Reports  (10/22/19)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. More >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis
Source: Streetwise Reports  (10/21/19)
The details of this study and a second one are outlined in a ROTH Capital Partners report. More >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher
Source: Streetwise Reports  (10/18/19)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. More >

Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data
Source: Streetwise Reports  (10/17/19)
Shares of Protalix Biotherapeutics skyrocketed today on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. More >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer
Source: Streetwise Reports  (10/16/19)
Shares of Achillion Pharmaceuticals are trading much higher today after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. More >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho
Source: Streetwise Reports  (10/16/19)
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. More >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results
Source: Streetwise Reports  (10/15/19)
Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. More >

Technical Analyst Expects Health Technologies Firm to Break Higher
Source: Clive Maund for Streetwise Reports  (10/14/19)
Technical analyst Clive Maund outlines the reasons this stock might break higher. More >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million
Source: Streetwise Reports  (10/14/19)
Shares of Cerecor Inc. are trading higher today after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. More >

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company
Source: Clive Maund for Streetwise Reports  (10/12/19)
Technical analyst Clive Maund believes this stock could gain traction soon. More >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights
Source: Streetwise Reports  (10/11/19)
Shares of Reata Pharmaceuticals are trading 12% higher today after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. More >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid
Source: Streetwise Reports  (10/10/19)
Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. More >

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial
Source: Streetwise Reports  (10/8/19)
Data from this study should be released by the end of this year. More >

Coverage Initiated on U.S.-Based Precision Therapy Developer
Source: Streetwise Reports  (10/8/19)
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. More >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%
Source: Streetwise Reports  (10/7/19)
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. More >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial
Source: Streetwise Reports  (10/3/19)
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. More >

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'
Source: Streetwise Reports  (9/30/19)
The latest clinical trial results are dissected in a ROTH Capital Partners report. More >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer
Source: Streetwise Reports  (9/30/19)
Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. More >

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study
Source: Streetwise Reports  (9/27/19)
Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. More >

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results
Source: Streetwise Reports  (9/26/19)
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. More >

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials
Source: Streetwise Reports  (9/25/19)
The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease. More >

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results
Source: Streetwise Reports  (9/25/19)
The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. More >

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'
Source: Streetwise Reports  (9/24/19)
The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. More >

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial
Source: Streetwise Reports  (9/24/19)
Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. More >

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study
Source: Streetwise Reports  (9/23/19)
Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. More >